These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 12469228

  • 1. Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats.
    Courtois P, Jijakli H, Ladriere L, Oguzhan B, Sener A, Malaisse WJ.
    Int J Mol Med; 2003 Jan; 11(1):105-9. PubMed ID: 12469228
    [Abstract] [Full Text] [Related]

  • 2. Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats.
    Laghmich A, Ladrière L, Malaisse-Lagae F, Malaisse WJ.
    Pharmacol Res; 1999 Dec; 40(6):475-82. PubMed ID: 10660944
    [Abstract] [Full Text] [Related]

  • 3. Comparison of insulinotrophic actions of nateglinide with glibenclamide dissociated from absorption in conscious dogs.
    Okamoto M, Ogihara N, Kawamura W, Ebihara S, Takiguchi K, Morita T, Uchida R, Yamaguchi J, Sakai T, Okuda Y, Hayashi Y, Arakawa Y, Kikuchi M.
    Metabolism; 2002 May; 51(5):575-81. PubMed ID: 11979388
    [Abstract] [Full Text] [Related]

  • 4. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
    Ikenoue T, Okazaki K, Fujitani S, Tsuchiya Y, Akiyoshi M, Maki T, Kondo N.
    Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209
    [Abstract] [Full Text] [Related]

  • 5. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC.
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [Abstract] [Full Text] [Related]

  • 6. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
    Kawai J, Ohara-Imaizumi M, Nakamichi Y, Okamura T, Akimoto Y, Matsushima S, Aoyagi K, Kawakami H, Watanabe T, Watada H, Kawamori R, Nagamatsu S.
    Biochem J; 2008 May 15; 412(1):93-101. PubMed ID: 18254725
    [Abstract] [Full Text] [Related]

  • 7. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
    Mori Y, Kitahara Y, Miura K, Mine T, Tajima N.
    Diabetes Obes Metab; 2004 Nov 15; 6(6):422-31. PubMed ID: 15479218
    [Abstract] [Full Text] [Related]

  • 8. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
    McLeod JF.
    Clin Pharmacokinet; 2004 Nov 15; 43(2):97-120. PubMed ID: 14748619
    [Abstract] [Full Text] [Related]

  • 9. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).
    Ikenoue T, Akiyoshi M, Fujitani S, Okazaki K, Kondo N, Maki T.
    Br J Pharmacol; 1997 Jan 15; 120(1):137-45. PubMed ID: 9117089
    [Abstract] [Full Text] [Related]

  • 10. Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes.
    Kitahara Y, Miura K, Takesue K, Mine T, Wada R, Uchida Y, Ito S, Yagihashi S.
    Metabolism; 2002 Nov 15; 51(11):1452-7. PubMed ID: 12404197
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic alpha- and beta-cells: comparative study with glibenclamide.
    Hirose H, Maruyama H, Seto Y, Ito K, Fujita T, Dan K, Kanda N, Saruta T, Kato R.
    Pharmacology; 1995 Mar 15; 50(3):175-81. PubMed ID: 7746834
    [Abstract] [Full Text] [Related]

  • 15. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
    Kahn SE, Montgomery B, Howell W, Ligueros-Saylan M, Hsu CH, Devineni D, McLeod JF, Horowitz A, Foley JE.
    J Clin Endocrinol Metab; 2001 Dec 15; 86(12):5824-9. PubMed ID: 11739446
    [Abstract] [Full Text] [Related]

  • 16. Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats.
    Mori Y, Ojima K, Fuujimori Y, Aoyagi I, Kusama H, Yamazaki Y, Kojima M, Shibata N, Itoh Y, Tajima N.
    Endocrine; 2006 Apr 15; 29(2):309-15. PubMed ID: 16785606
    [Abstract] [Full Text] [Related]

  • 17. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
    Karara AH, Dunning BE, McLeod JF.
    J Clin Pharmacol; 1999 Feb 15; 39(2):172-9. PubMed ID: 11563410
    [Abstract] [Full Text] [Related]

  • 18. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR.
    Diabetes Metab Res Rev; 2002 Feb 15; 18(6):484-90. PubMed ID: 12469362
    [Abstract] [Full Text] [Related]

  • 19. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.
    Mine T, Miura K, Kitahara Y, Okano A, Kawamori R.
    Biol Pharm Bull; 2002 Nov 15; 25(11):1412-6. PubMed ID: 12419950
    [Abstract] [Full Text] [Related]

  • 20. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
    Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.
    Intern Med; 2007 Nov 15; 46(22):1837-46. PubMed ID: 18025765
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.